MDCLF Stock Chart & Stats
$34.39
$27.41(393.00%)
At close: 4:00 PM EST
$34.39
$27.41(393.00%)
Day’s Range― - ―
52-Week Range$6.97 - $34.39
Previous CloseN/A
Volume390.00
Average Volume (3M)0.00
Market Cap
$908.64M
Enterprise Value$731.65
Total Cash (Recent Filing)$84.82M
Total Debt (Recent Filing)$57.41M
Price to Earnings (P/E)―
Beta-0.80
Next Earnings
Dec 08, 2026EPS Estimate
-0.25Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.91
Shares Outstanding35,924,610
10 Day Avg. Volume0
30 Day Avg. Volume0
Financial Highlights & Ratios
PEG Ratio-0.68
Price to Book (P/B)264.15
Price to Sales (P/S)41.46
P/FCF Ratio-30.43
Enterprise Value/Market Cap<0.01
Enterprise Value/Revenue<0.01
Enterprise Value/Gross Profit<0.01
Enterprise Value/Ebitda>-0.01
Forecast
1Y Price Target
$44.13Price Target Upside28.31% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering1
EPS Forecast (FY)-0.02
Revenue Forecast (FY)$55.23M
Bulls Say, Bears Say
Bulls Say
UZEDY Commercial MomentumRapid UZEDY sales growth is converting MedinCell’s delivery technology into expanding royalty income, a more recurring revenue stream than milestone payments. Continued prescription growth can strengthen cash generation and provide a commercial base for funding additional platform programs.
Olanzapine LAI Regulatory ProgressAcceptance of the olanzapine LAI NDA and submission of the European application materially advance a potential second commercial royalty engine. The product’s clinical injection record and planned launch could broaden revenue beyond UZEDY if approvals and partner execution remain on schedule.
Expanding Partnered PipelineA broad formulation-stage portfolio increases the number of potential milestone and royalty opportunities while distributing development activity across internal and partner-funded programs. Progress with AbbVie also validates external demand for the platform and supports longer-term pipeline depth.
Bears Say
Persistent Losses And Cash BurnMaterial losses and renewed operating cash burn show that the business has not yet achieved sustainable operating leverage. Although debt is reported at zero, continued investment requires liquidity or future monetization progress, making execution and funding discipline important over the coming periods.
Milestone-driven Revenue VolatilityThe absence of a milestone caused reported income to decline despite progress in royalty revenue, demonstrating that results remain exposed to irregular contractual events. This volatility can complicate planning and makes the timing of development and regulatory achievements financially consequential.
Partner And Regulatory Execution RiskMedinCell’s partnered model provides access to commercial and development resources but leaves important outcomes dependent on partners’ decisions, launches and guidance. Regulatory uncertainty and possible program delays can therefore defer royalties, milestones and the expected return on platform investment.
MedinCell SA News
MDCLF FAQ
What was MedinCell SA’s price range in the past 12 months?
MedinCell SA lowest stock price was $6.97 and its highest was $34.39 in the past 12 months.
What is MedinCell SA’s market cap?
MedinCell SA’s market cap is $908.64M.
When is MedinCell SA’s upcoming earnings report date?
MedinCell SA’s upcoming earnings report date is Dec 08, 2026 which is in 87 days.
How were MedinCell SA’s earnings last quarter?
MedinCell SA released its earnings results on Jun 16, 2026. The company reported -$0.521 earnings per share for the quarter, missing the consensus estimate of -$0.162 by -$0.359.
Is MedinCell SA overvalued?
According to Wall Street analysts MedinCell SA’s price is currently Undervalued.
Does MedinCell SA pay dividends?
MedinCell SA does not currently pay dividends.
What is MedinCell SA’s EPS estimate?
MedinCell SA’s EPS estimate is -0.25.
How many shares outstanding does MedinCell SA have?
MedinCell SA has 35,924,610 shares outstanding.
What happened to MedinCell SA’s price movement after its last earnings report?
MedinCell SA reported an EPS of -$0.521 in its last earnings report, missing expectations of -$0.162. Following the earnings report the stock price went same 0%.
Which hedge fund is a major shareholder of MedinCell SA?
Currently, no hedge funds are holding shares in MDCLF
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
MedinCell SA
MedinCell S.A. specializes in pioneering diverse therapeutic treatments. At the core of its development lies BEPO, a cutting-edge technology that enables the creation of long-acting injectable pharmaceutical products. This system leverages a unique combination of proprietary copolymers and a biocompatible solvent to effectively dissolve or suspend active drug compounds. The company's advanced pipeline includes several key products: mdc-IRM, a subcutaneous injection currently in Phase III clinical trials for the treatment of schizophrenia; mdc-CWM, an intra-articular injection designed to address pain and inflammation; and mdc-TJK, another subcutaneous injection targeting schizophrenia, presently in preclinical development. MedinCell is also actively engaged in formulation research for additional product candidates. These encompass subcutaneous injections such as mdc-WWM for contraception, mdc-ANG for central nervous system-related conditions, mdc-ELK for depression, and mdc-GRT for organ transplant applications. Furthermore, the firm is investigating perineural injections like mdc-CMV for anesthesia and pain management, and mdc-NVA, also intended for pain relief. MedinCell S.A. maintains its headquarters in Jacou, France.
MDCLF Stock 12 Month Forecast
Average Price Target
$44.13
▲(28.31% Upside)
Technical Analysis
Ownership Overview
―
Insiders
2.79% Mutual Funds
― Other Institutional Investors
95.58% Public Companies and
Individual Investors